Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Farhad Ravandi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, PhD, Stuart L. Goldberg, MD, Meir Wetzler, MD, Parameswaran Venugopal, MD, Karen Seiter, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2630.

https://doi.org/10.1182/blood.V120.21.2630.2630

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Kathy M. Tran, Syed M. Kazmi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Stefan Faderl, MD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD

Blood (2012) 120 (21): 2592.

https://doi.org/10.1182/blood.V120.21.2592.2592

Published: 2012

Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2562.

https://doi.org/10.1182/blood.V120.21.2562.2562

Published: 2012

Journal Articles

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Farhad Ravandi, MD, Keyur P. Patel, MD, PhD, Rajyalakshmi Luthra, Ph.D., Sherry A. Pierce, RN, BS, Gautam Borthakur, M.D., Elias J. Jabbour, MD, Tapan M. Kadia, M.D., Naveen Pemmaraju, M.D., Naval Daver, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jorge E Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2483.

https://doi.org/10.1182/blood.V120.21.2483.2483

Published: 2012

Journal Articles

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Elias J. Jabbour, MD, Naval G. Daver, MD, Tina (Xiao Qin) Dong, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, M.D., Hady Ghanem, MD, Stefan Faderl, MD, Gautam Borthakur, M.D., Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 2824.

https://doi.org/10.1182/blood.V120.21.2824.2824

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

Farhad Ravandi, MD, Mona Lisa Alattar, MD, Mark J. Levis, MD, PhD, Guillermo Garcia-Manero, MD, Mary A Richie, RN, Naval G. Daver, MD, Stefan Faderl, MD, Michael Andreeff, MD, PhD, Gautam Borthakur, M.D., Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Michael R. Grunwald, MD, Sara E Dellasala, RN, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 1519.

https://doi.org/10.1182/blood.V120.21.1519.1519

Published: 2012

Journal Articles

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 1693.

https://doi.org/10.1182/blood.V120.21.1693.1693

Published: 2012

Journal Articles

Transglutaminase2 Expression in Acute Myeloid Leukemia: Association with Adhesion Molecule Expression and Leukemic Blast Motility

Steven M. Kornblau, MD, PhD, Andrew Pierce, Stefan Meyer, Farhad Ravandi, MD, Gautam Borthakur, M.D., Kevin R. Coombes, PhD, Nianxiang Zhang, Anthony Whetton

Blood (2012) 120 (21): 1427.

https://doi.org/10.1182/blood.V120.21.1427.1427

Published: 2012

Journal Articles

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Blood (2012) 120 (21): 3572.

https://doi.org/10.1182/blood.V120.21.3572.3572

Published: 2012

Journal Articles

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

Blood (2012) 120 (21): 677.

https://doi.org/10.1182/blood.V120.21.677.677

Published: 2012

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Aziz Nazha, Hagop M. Kantarjian, MD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Zeev Estrov, MD, PhD, Elias Jabbour, Alfonso Quintas-Cardama, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3587.

https://doi.org/10.1182/blood.V120.21.3587.3587

Published: 2012

Journal Articles

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Koichi Takahashi, MD, Elias J. Jabbour, MD, Xuemei Wang, MS, Hady Ghanem, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3802.

https://doi.org/10.1182/blood.V120.21.3802.3802

Published: 2012

Journal Articles

Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia

Paolo Strati, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Gautam Borthakur, M.D., Stefan Faderl, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3766.

https://doi.org/10.1182/blood.V120.21.3766.3766

Published: 2012

Journal Articles

A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, PhD, Gautam Borthakur, M.D., Susan M. O'Brien, MD, Tapan M. Kadia, M.D., Marina Konopleva, MD, PhD, Naval Daver, MD, Mark Brandt, BS, Heather Schroeder, RN, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 3851.

https://doi.org/10.1182/blood.V120.21.3851.3851

Published: 2012

Journal Articles

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Farhad Ravandi, Cielo Foudray, Naveen Pemmaraju, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Naval G. Daver, MD, Stefan Faderl, MD, Elias Jabbour, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3821.

https://doi.org/10.1182/blood.V120.21.3821.3821

Published: 2012

Journal Articles

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Rajyalakshmi Luthra, Ph.D., Alfonso Quintás-Cardama, M.D., Elias J. Jabbour, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3781.

https://doi.org/10.1182/blood.V120.21.3781.3781

Published: 2012

NARROW

Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles.

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3 -ITD mutation

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Transglutaminase2 Expression in Acute Myeloid Leukemia: Association with Adhesion Molecule Expression and Leukemic Blast Motility

Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Hypercvad Plus Imatinib or Dasatinib for Patients with Lymphoid Blastic Phase of Chronic Myeloid Leukemia

A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only